Cleared Traditional

K201223 - LZI Tramadol Enzyme Immunoassay (FDA 510(k) Clearance)

Jun 2020
Decision
29d
Days
Class 2
Risk

K201223 is an FDA 510(k) clearance for the LZI Tramadol Enzyme Immunoassay. This device is classified as a Enzyme Immunoassay, Opiates (Class II - Special Controls, product code DJG).

Submitted by Lin-Zhi International, Inc. (Santa Clara, US). The FDA issued a Cleared decision on June 4, 2020, 29 days after receiving the submission on May 6, 2020.

This device falls under the Toxicology FDA review panel. Regulated under 21 CFR 862.3650.

Submission Details

510(k) Number K201223 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 06, 2020
Decision Date June 04, 2020
Days to Decision 29 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF

Device Classification

Product Code DJG — Enzyme Immunoassay, Opiates
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.3650

Similar Devices — DJG Enzyme Immunoassay, Opiates

All 23
Labcorp Fentanyl Urine Visual Test
K252684 · Medtox Diagnostics, Inc. · Jan 2026
LZI Buprenorphine II Enzyme Immunoassay
K253082 · Lin-Zhi International, Inc. · Jan 2026
SEFRIA™ Hydrocodone Oral Fluid
K252520 · Immunalysis Corporation · Sep 2025
Healgen® AccuFluor Fentanyl Fluorescence Immunoassay (FIA)Test Kit - Qualitative
K251972 · Healgen Scientific, LLC · Aug 2025
LZI Fentanyl III Enzyme Immunoassay
K251634 · Lin-Zhi International, Inc. · Jun 2025
CEDIA Heroin Metabolite (6-AM) Assay
K231007 · Microgenics Corporation · Sep 2023